life scienc tool diagnost forecast reduct
ep top consensu abc ep beat
better revenu profit factor line ad importantli
unveil initi guidanc call revenu growth msd-hsd ep
well consensu estim midpoint
reflect onboard inher lower margin new esrx/ci busi
lower ep reflect lower profit experi
revenu profit impress revenu improv vs estimate distribut
incl specialti acquisit rise view vs estimate rose
far exceed plan repres profit compon
posit thesi gross margin bp bp plan oper expens
bp bp higher plan ebit margin flat y/i bp
lower plan focu area oper profit distribut climb estimate
gener billion million oper cash flow fund million
share repurchas million dividend
share rise initi guidanc reflect subdu profit experi
share grind higher today acknowledg caveat guid
includ esrx/ci vaccin sale time leas account
chang headwind pharma op profit note manag commentari opioid
seemingli optimist potenti global settlement well guidanc call
lsd-msd dist oper profit growth includ lsd-msd distribut
hsd lower anticip still maintain posit thesi
view distributor better posit rel peer predic driver
larg pharmaci relationship contribut non-cor unit well strong
cash flow characterist billion risk demand opioid litig
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
global pharmaceut sourc distribut
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead downsid
versu target price grey sky scenario
 close
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
